A Sterne, Kessler, Goldstein and Fox litigation team represented TwinStrand Biosciences, Inc. and the University of Washington in a federal patent infringement case against Guardant Health. On November 14, 2023, the jury awarded $83.4 million in past damages, and also found that Guardant Health willfully infringed the two asserted patents by the sale of Guardant’s FDA-approved Guardant 360 CDx product, as well as all of its other commercial products in cancer screening, detection, and characterization. The patents at issue were U.S. Patent No. 10,760,127 and U.S. Patent No. 10,287,631, both owned by the University of Washington and exclusively licensed to TwinStrand Biosciences. TwinStrand was founded by the inventors of the patents.
The Sterne Kessler trial team was led by Directors Byron L. Pickard and R. Wilson “Trey” Powers III and included fellow Directors Chandrika Vira, William H. Milliken, Anna G. Phillips and Tyler J. Dutton, along with Counsel, Christopher M. Gallo and Associates Matthew M. Zuziak, Brady P. Gleason, Louis P. Panzica, Ryan N. Kaiser, Jamie Dohopolski, and John Hylton.
Sterne Kessler also successfully handled several related matters on behalf of TwinStrand at the US Patent Trial and Appeal Board (PTAB) upholding the validity of all challenged claims. Coverage of the cases is available here.